Cangrelor tetrasodium and Lorcaserin Hydrochloride

• Generic Name: cangrelor
• Dosage Forms: n.a.
• Other Brand Names: Kengreal

Used as an adjunct to PCI to reduce the risk of periprocedural MI, repeat coronary revascularization, and stent thrombosis in patients who have not been treated with a P2Y12-receptor antagonist and are not being given a glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor.

Dual-drug antiplatelet therapy with a P2Y12-receptor antagonist and aspirin is part of the current standard of care in patients with acute coronary syndromes (ACS).

Potential advantages of cangrelor include rapid onset and offset of effect and less interindividual variability in antiplatelet effect (i.e., compared with clopidogrel).

Precise role of cangrelor in the management of ACS remains to be established.

• Generic Name: lorcaserin
• Dosage Forms: n.a.
• Other Brand Names: Belviq, Belviq XR

Adjunct to caloric restriction and increased physical activity in the chronic management of obesity.

Used in patients who are obese (pretreatment body mass index [BMI] ≥30 kg/m2); also used in overweight patients with pretreatment BMI ≥27 kg/m2 in the presence of a weight-related risk factor or disease (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia).

Indicated only for monotherapy; safety and efficacy in combination with other weight loss products (prescription drugs [e.g., phentermine], OTC drugs, herbal preparations) not established.

Long-term effects on cardiovascular morbidity and mortality associated with obesity not established; safety and efficacy beyond 2 years of use not established.